An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2028

Conditions

Autoimmune Diseases

Interventions

DRUG

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.

A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.

Trial Locations (1)

RECRUITING

Hunan Siweikang Therapeutic Co.Ltd, Changsha

All Listed Sponsors

lead

The First Affiliated Hospital of University of Science and Technology of China

OTHER